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Abstract
The transforming growth factor-β (TGF-β) signaling pathway regulates various cellu-
lar processes during tissue and organ development and homeostasis. Deregulation of 
the expression and/or functions of TGF-β ligands, receptors or their intracellular signal-
ing components leads to multiple diseases including vascular pathologies, autoimmune 
disorders, fibrosis and cancer. In vascular development, physiology and disease TGF-β 
signaling can have angiogenic and angiostatic properties, depending on expression levels 
and the tissue context. The objective of this chapter is to analyze the mechanisms that 
contribute to the activation and signaling of TGF-β in developmental, physiological and 
pathological angiogenesis, with a particular emphasis on the importance of TGF-β signal-
ing in the mammalian central nervous system (CNS).
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1. Introduction
Discovery of TGF-βs was the result of independent efforts by several laboratories [1–4] during 
characterization of a secreted factor from fibroblasts transformed by the Moloney sarcoma 
virus (MSV). The TGF-β superfamily is now known to be composed of more than 30 che-
mokines such as TGF-β1-β3, activins, anti-Müllerian hormone (AMH), bone morphogenetic 
proteins (BMPs), growth and differentiation factors (GDFs) and NODAL that can signal via 
canonical and noncanonical receptors and intracellular effector proteins [5].
The best characterized member of the TGF-β family, TGF-β1, is initially produced from a 
single gene as a large precursor known as pre- and pro-TGF-βs which undergo two proteo-
lytic cleavage events. The first signal peptide is cleaved in the rough endoplasmic reticu-
lum. Furin, a proprotein convertase, subsequently cleaves the protein into two fragments [6]. 
The carboxy terminus corresponds to the functionally active cytokine and the large amino 
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 terminus is latency-associated protein (LAP), also referred to as the prodomain. Regardless 
of this processing by furin, the mature and LAP domains remain associated by noncovalent 
bonds to form the small latent complex (SLC). This complex subsequently covalently interacts 
with a second gene product, the latent TGF-β binding protein (LTBP), and is incorporated into 
a larger latent complex (LLC) that associates with the extracellular matrix (ECM) [6]. Three-
dimensional crystal structure of porcine latent TGF-β1 shows a conformation that resembles 
a ring-like shape [7]. Two domains were defined in the structure: (i) an arm domain that con-
tains an integrin-binding Arg-Gly-Asp (RGD) peptide motif and (ii) a “straitjacket” domain 
where the mature TGF-β is encased. At the opposite end of the arm domain, LTBP binds the 
prodomain forming the “ring head” [7] (Figure 1).
After secretion, the LLC complex interacts with various ECM proteins, such as fibronectin and 
fibrillin, and is maintained in an inactivated form [8]. TGF-β is activated by different mecha-
nisms, including interactions with integrins, alterations in pH and extracellular proteases. αν 
integrin, which forms heterodimers with five different β integrin subunits (β1, β3, β5, β6 and 
β8), that bind to LAP-TGF-β1 and LAP-TGFβ-3 [9, 10]. However, only ανβ6 and ανβ8 have 
been shown to activate the latent TGF-β complex [11]. Activation by both ανβ6 and ανβ8 
integrins requires the RGD motif in LAP. Activation by ανB6 requires an intact cytoplasmic 
domain [12, 13] and the presence of other ECM proteins [14]. Activation by ανβ8, however, 
Figure 1. TGF-β processing and activation. (a)TGF-β precursor undergoes proteolysis at its N-terminus (black arrow 
head) which results in the removal of its signal peptide. (b)In a second proteolytic cleavage event by furin (blue arrow 
head), the precursor is separated into a large LAP or prodomain (gray) and the mature TGF-β (red) and (c)Schematic 
view of the closed ring structure (left) and unfastened straitjacket (right) conformation corresponding to the inactive 
LAP-TGF-β and mature TGF-β, respectively.
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does not require the integrin cytoplasmic domain, but it is reported to require the presence 
of metalloproteinases (MMPs) on the cell surface or in the ECM [9]. Additionally, in T cells, 
ανβ6 and ανβ8 can activate LAP-TGF-β in cooperation with the glycoprotein-A repetitions 
predominant protein (GARP) [15, 16].
TGF-β is also activated by proteases. Aspartyl (e.g., cathepsin D) [17], cysteine (e.g., calpain) 
[18] and serine proteases (e.g., plasmin and kallikreins) and metalloproteases have shown to 
stimulate the release of chemokine from the latent complex, although most of these studies 
have been performed in vitro [19]. Moreover, TGF-β has been reported to be activated by other 
nonprotease mechanisms such as neuropilin1 (Nrp1), thrombospondin (TSP-1), F-spondin, 
pregnancy-specific beta-1-glycoprotein 1 (PSG1) and deglycosylation. Likewise, there are 
chemical and physical settings that activate TGF-β, for example, heat, ultraviolet radiation, 
physical shear, detergents and reactive oxygen species [8].
Three-dimensional structural studies of the LLC reveal that the RGD motifs are readily avail-
able for integrin engagement. Hydrophobic side chains, which have been identified near the 
RGD motif, likely enhance integrin binding [7]. In the presence of ανβ6, LLC can bind one 
or two integrin monomers. However, this binding does not induce required conformational 
changes to promote the complete activation of TGF-β, which is in agreement with prior muta-
tional studies [12, 13, 20]. Furthermore, in accord with previous studies, the crystal structure 
of latent TGF-β predicts that pulling forces, emanating from the integrin C-terminal cytoplas-
mic tail that interacts with the cytoskeleton and binding RGD via the N-terminal extracellular 
region, are counteracted by associations with the ECM. Therefore, in the latent TGF-β, the 
straitjacket domain is maintained in a closed conformation until tensile forces are applied 
from both ends of the structure, resulting in loosening of the straitjacket domain and the 
release of the mature TGF-β. This study also showed that an additional feature of the prodo-
main is to prevent access to activating receptors [7].
2. TGF-β signaling pathways
Signaling is regulated by three major receptors: TGF-β receptor type I (TβRI), type II (TβRII) 
and type III (TβRIII). In general, TGF-β binds TβRIII, which facilitates its delivery to TβRII, 
a constitutively active kinase, leading to the subsequent phosphorylation and activation of 
TβRI. In humans, there are seven TβRIs, also known as activin receptor-like kinases (ALK), 
and five TβRIIs [5]. In most cells, ALK-5 forms a heterodimer with TβRII bound to TGF-β, 
which activates the ALK-5 kinase domain via phosphorylation of its GS domain. This recep-
tor activation propagates intracellular signaling through ‘canonical’ effector proteins moth-
ers against decapentaplegic homolog 2/SMAD family member 2 (Smad2) and Smad3, which 
are transcription factors. Once phosphorylated, these Smad proteins form a complex with 
Smad4 leading to nuclear translocation and initiation of genes transcription. In most normal 
cells, TGF-β-mediated activation of Smads leads to inhibition of cell growth. More specifi-
cally, the Smad2/3-4 complex partners with foxhead box O (FOXO) factors to activate p21Cip1 
(CDKN1A), which inhibits cyclin-dependent kinase 1(CDK1), resulting in cell cycle arrest. 
Similarly, TGF-β can also activate p15Inkab (CDKN2B), the CDK4 inhibitor, through the 
SMAD2-3/4-FOXO1 axis (Figure 2) [5].
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Likewise, TGF-β acts as a cytostatic factor by decreasing c-Myc expression and downregulat-
ing the inhibitor of DNA-binding protein (ID) 1 and ID3 transcription factors. ID1 and ID3 
are involved in differentiation, cell cycle progression and self-renewal of stem cells [21, 22]. 
TGF-β elicits c- Flk-1myc repression by promoting SMAD3 binding to a repressing Smad-
binding element (RSBE) at the c-myc promoter [23]. c-Myc can be recruited to the promot-
ers of CDKN1A and CDKN2B by the Myc-interacting zinc-finger (MIZ-1). This blocks CDK 
expression and results in apoptosis [24]. Additionally, in endothelial cells (ECs), TGF-β can 
target a second receptor type 1, ALK-1, which signals through Smad1/5/8 and stimulates 
angiogenic factors, such as interleukin 1 receptor-like 1 and ID1 (Figure 2) [25].
Several proteins are known to antagonize canonical TGF-β signaling. For example, (i) PI3K 
activates AKT which phosphorylates the SMADs-FOXO complex and inhibits its transloca-
tion to the nucleus [21], (ii) foxhead box G1 (FOXG1) inhibits the SMADs-FOXO complex [21], 
(iii) SMAD7 can trigger TβRI for proteosomal degradation by recruiting SMAD-specific E3 
ubiquitin protein ligase (SMURF1) and SMURF2 [26], (iv) SMAD6 blocks SMAD1 through 
SMAD4 binding, (v) Erk proteins phosphorylate SMADs and inhibit their nuclear translo-
cation, (vi) BAMBI, a pseudoreceptor, dimerizes with TβRI leading to its inactivation, (vii) 
FKBP12 binds to TβRI and impedes its phosphorylation, activation and signaling [27] and 
(viii) protein arginine N-methyltransferase 1 (PRMT1) methylates SMAD6 and allows BMP 
signaling through SMADs1/5 [28–30].
Figure 2. TGF-β canonical pathway. (a)In normal cells and early stages of cancer TGF-β promotes cell cycle arrest. 
Repressors of the pathway are shown in red. Blue dots represent protein phosphorylation and (b)in endothelial cells, an 
alternative pathway promotes cell proliferation.
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3. Vasculogenesis
During embryogenesis, the development of the vascular system is divided into three stages, 
vasculogenesis, angiogenesis and arteriogenesis. Vasculogenesis occurs in embryonic organs 
as well as extraembryonic tissues such as the placenta, yolk sac and allantois [31]. The earliest 
discernible structures in vasculogenesis, the blood islands, are formed in the mouse yolk sac 
by embryonic day (E) 6.5–7. This structure contains precursor cells or hemangioblasts, which 
differentiate to EC and hematopoietic cells [32]. At E8.5, cells located toward the periphery of 
the blood island, or angioblasts, differentiate into EC, while cells located toward the central 
region give rise to hematopoietic precursor cells. Next, lumenization takes place; tight junc-
tions and basement membranes develop, and pericytes are recruited to blood vessels and 
promote maturation [33].
Several growth factors have been identified to regulate vasculogenesis, such as vascular 
endothelial growth factor (VEGF), fibroblast growth factor (FGF), the hedgehog family, neu-
ropilins, integrins, fibronectin and TGF-βs. FGF-2 has been reported to participate in the gen-
eration of the angioblast in quail/chick chimeras and in vessel formation [34].
Hedgehog signaling has been shown to be crucial in the initial steps of vasculogenesis. It 
promotes differentiation of the primitive endoderm into both, endothelial and hematopoietic 
lineage [35]. For instance, blocking Indian hedgehog (Ihh) causes signaling repression from 
the visceral ectoderm and consequently abrogation of vasculogenesis and hematopoiesis in 
anterior epiblast [35]. Deletion of Ihh in mouse caused 50% lethality at midgestation with 
the remaining 50% dying at birth. Defects in blood vessel formation have been proposed as 
the cause for the lethality, which has been supported by experiments showing: (i) deletion 
of Sonic hedgehog (Shh) in mice resulted in a reduction in vascularization in lung [36], (ii) 
overexpression of Shh resulted in an increase in vascularization in neuroectoderm [37], (iii) 
depletion of Shh in zebrafish caused defective vasculature [38] and (iv) depletion of Ihh from 
stem cell-derived embroid bodies inhibited blood island differentiation [39].
VEGF signaling is crucial in vasculogenesis. Genetic studies have shown that deletion of Flt-1 
(VEGFR1), Flk-1/KDR (VEGFR2) and one or both alleles of VEGF cause embryonic lethality. 
VEGFR1 mutants exhibit aberrant central localization of the angioblasts in the blood island, 
instead of their normal localization toward the periphery [40]. These results implied that the 
growth of ECs was not inhibited in this region and led to the idea that VEGR1 hampers signal-
ing from VEGF by ligand sequestration [33]. In addition, VEGFR2 mutants die around E9. In 
these embryos, both vasculogenesis and hematopoiesis do not initiate which was explained 
by faulty blood island in which cell migration was abrogated [41, 42]. Similarly, mutant het-
erozygous for VEGF die by E11 and showed impaired vasculogenesis and angiogenesis. These 
embryos showed severe abnormalities, such as underdeveloped brain and heart, decreased 
number of nucleated red blood cells in blood islands and aberrant vasculature in nervous 
system and placenta [43].
Neuropilins are co-receptors for VEGF receptors. Nrp1 is found in ECs of arteries, while neu-
ropilin 2 (Nrp2) is found at the endothelium of lymphatic vessels and veins. Deletion of Nrp1 
in mice affects severely the central and peripheral nervous systems, as well as the yolk sac 
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vasculature [44]. In contrast, depletion of Nrp2 has no effects in the vasculature of arteries or 
veins, but it does affect angiogenesis of the lymphatic vasculature [45, 46]. In addition, mice 
harboring deletions in both neuropilins have shown obstruction in vasculogenesis in the yolk 
sac and in the formation of the primary vascular plexus [47].
4. Developmental angiogenesis
Angiogenesis is the formation of new blood vessels from existing vasculature. It occurs 
by mechanisms including sprouting angiogenesis and intussusceptive angiogenesis 
(Figure 3). Sprouting angiogenesis initiates with the selection of endothelial tip cells 
at the vessel wall. These cells react toward extracellular stimuli and secrete proteolytic 
enzymes to digest the surrounding ECM. Tip cells are connected to endothelial stalk 
cells to direct the vascular sprout [33, 48, 49]. Once the new tube is formed and a lumen is 
established, the vessel is stabilized by the recruitment of pericytes to capillaries or vascu-
lar smooth muscle cells (vSMC) to arteries and veins [6, 33], leading to re-establishment 
of mature blood vessels.
Intussusceptive angiogenesis, also known as splitting angiogenesis, results in the formation of 
intermediate intracapillary pillars. This mechanism is more efficient than sprouting angiogen-
esis since it does not require cell proliferation. Instead, it needs the reorganization of existing 
ECs. In this process, (i) ECs from opposite sides of the blood vessel make contacts, (ii) ECs 
from both ends reorganize and cause a splitting in the vessel wall, (iii) an interstitial pillar 
core is generated and (iv) myofibroblasts, pericytes and finally collagen invade the pillar and 
a basement membrane is formed [33, 49, 50].
5. TGF-β in vasculogenesis and angiogenesis
5.1. Mutant phenotypes in mice lacking components of the TGF-B pathway
TGF-β mRNA was initially detected by PCR in preimplantation stages and in situ expression 
was present as early as E7.5, suggesting important roles in early development [51, 52]. In 
the embryo, proper TGF-β was detected in angioblast progenitors within the primitive heart 
mesoderm. Likewise, its expression was detected in extraembryonic tissues, including in the 
allantois mesoderm, and within blood islands of the yolk sac [53].
Figure 3. Mechanisms of angiogenesis. (a)Sprouting and (b)intussusceptive angiogenesis.
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Deletion of the TGF-β1 gene in mice resulted in 50% lethality in utero, with the remaining 50% 
of mutant mice surviving up to three weeks postnatally. Histopathology analyses showed 
multifocal inflammatory cell infiltration and necrosis in several organs, especially the heart 
and stomach [53, 54]. It was subsequently shown that maternal contributions of TGFB1 RNA 
and other genetic and epigenetic factors contributed to 50% postnatal survival [55].
The 50% of TGF-β mutants showed lethality and resorption by E10.5. Analysis of E8.5 embryos 
did not show significant morphological defects. However, analysis of E9.5 and E10.5 embryos 
resulted in a range of phenotypic defects within the yolk sac. While in some cases, vasculo-
genesis was delayed; in other cases, a dramatic reduction in size was observed and it was 
accompanied by weak and disorganized primary vessels, with some areas displaying com-
plete vessel depletion. Analysis of the yolk sac vasculature indicated that the defects occurred 
during differentiation of ECs and hematopoietic cells. In contrast, the initial differentiation of 
mesodermal cells into ECs was not affected [52].
Genetic ablation of TβRII resulted in very similar phenotypes as in TGF-β1 mutants, with 
alterations in yolk sac vasculature and embryonic lethality by E10.5- E11.5 [56]. Mutants in 
endoglin also showed defects in vascular vessels within and outside the embryo. Embryo 
lethality was observed at E11.5, with mutants developing focal hemorrhage [57, 58]. Similarly, 
engineered mutations in mice that abrogate the expression of ALK1, ALK5, SMAD1 or SMAD5 
resulted in defects in cardiovascular development [57, 59, 60].
5.2. Roles of TGF-β in angiogenesis
Early work to determine the roles for TGF-βs in ECs was contradictory. TGF-β signaling was 
initially found to inhibit cell migration and proliferation [61, 62], yet later studies indicated 
that it promotes cell proliferation [63–66]. The relative levels of expression of TGF-β seem to 
partially explain these discrepancies, with low doses promoting angiogenesis and higher lev-
els resulting in growth inhibition of ECs and maturation of blood vessels [66, 67]. For instance, 
during blood vessel coverage by smooth muscle cells, TGF-β paracrine signaling from ECs 
to mesenchymal cells results in vascular smooth muscle cell and pericyte differentiation [6].
TGF-β also plays a role in the angiogenic process of hypoxic tissue. For instance, during 
infarction (stroke), neovascularization occurs primarily at the ischemic penumbra (periphery 
of the infarct), which correlates with high levels of both mRNA and active TGF-β protein [68]. 
Similarly, during organ transplant VEGF and TGF-β1, levels are increased in devascularized 
hypoxic tissue. TGF-β3 was also upregulated in hypoxic tissues, but to a lesser degree [69].
TGF-β regulates angiogenesis by different mechanisms; for example, it is involved in ves-
sel proliferation and maturation by alternating two signaling cascades with opposite effects 
(ALK1 and ALK5). Likewise, TGF-β can promote its own expression, and it upregulates the 
expression of other angiogenic factors such as, platelet-derived growth factor (PDGF), inter-
leukine-1, basic fibroblast growth factor (bFGF), tumor necrosis factor alpha and transform-
ing growth factor alpha [70]. TGF-β can change the functions of other factors, such as VEGF, 
from prosurvival to pro-apoptotic [71]. Similarly, in vitro work has shown that in ECs TGF-β 
upregulates the expression of endothelin (EDN1), PDGFA and PDGFB, nitric oxide synthase 
TGF-β Activation and Signaling in Angiogenesis
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3 (NOS3), actin, alpha 2, smooth muscle, aorta (ACTA2), secreted protein acidic and cysteine 
rich (SPARC), TSP-1, fibronectin (FN1), collagens (COL1A1, COL4A1, and COL5A1), plasmin-
ogen activator (PLAU), serpin family E member 1 (SERPINE1) and integrins (ITGB1, ITGB3, 
ITGAV, ITGA2 and ITGA5). It can also downregulate several genes, such as selectin-E (SELE), 
KDR, von Willebrand factor (VWR), thrombomodulin (THBD), monocyte chemo-attractant 
protein (MCP1), C-X-C motif chemokine ligand 1 (CXCL1), integrins (ITGB1, ITGB3, ITGA5 
and ITGA6), TIMP1 and PLAU [70].
Levels of ALK1 and ALK5 determine TGF-β mitogenic or mitostatic responses in ECs. ALK5-
Smad2/3 signaling stimulates transcription of ECM proteins such as fibronectin and plas-
minogen activator inhibitor type 1, which promote the resolution of angiogenesis by inducing 
vessel maturation. In contrast, signaling via the ALK1-Smad1/5/8 pathway generates anti-
angiogenic responses [25, 51]. This requires a TGF-β accessory receptor, endoglin, which 
enhances ALK1 signaling and inhibits ALK5 cytostatic phenotype [72]. More recent work has 
shown that in the mouse eye retina the leucine-rich alpha-2-glycoprotein (Lrg1), which binds 
endoglin, promotes angiogenesis through Alk1-Smad1/5/8 in the presence of TGF-β [73].
5.2.1. TGF-β signaling in CNS development
In the mammalian CNS, neurons, astrocytes, pericytes and ECs closely interact to form a 
multicellular neurovascular unit [11]. During embryonic brain development, TGF-β is criti-
cal for sprouting angiogenesis of the CNS. In particular, TGF-β has been shown to work in 
conjunction with αν integrins to regulate paracrine signaling between neuroepithelial cells 
and ECs within neurovascular units. In mouse, embryos deletion of αν integrin showed vas-
cular defects that were restricted mainly to the brain. This phenotype was recapitulated in β8 
integrin mutant embryos. In contrast, deletion of β3 and β5 integrins did not cause brain vas-
culature abnormalities [74, 75]. Cell type-specific deletion of αν and β8 integrins in nervous 
system glial cells resulted in developmental intracerebral hemorrhage as well as postnatal 
motor dysfunction and seizures. Of note, the brain hemorrhage observed in embryos was 
absence in adult mice, suggesting that a compensatory mechanism that repairs hemorrhage 
occurs after birth [75, 76]. Interestingly, αν ablation in vascular ECs did not show a pheno-
type [75]. In later work, in which an outbred background was used to overcome the effects of 
β8−/− embryonic lethality, it was shown that adult mice lacking β8 integrin displayed neuro-
vascular pathologies [77]. Most notably, adult β8 integrin mutants displayed a reduction in 
olfactory bulb size and abnormalities at the subventricular zone and rostral migratory stream. 
Neuroblasts generated in the subventricular zone utilize blood vessels as guides to migrate 
within the rostral migratory stream and differentiated to neurons within the olfactory bulbs. 
The size-reduced olfactory bulbs in adult β8−/− mice revealed essential roles for this integrin 
in promoting neuroblast migration along blood vessels. These defects correlated with a reduc-
tion in TGF-β signaling in neurospheres dissected from β8−/− mice [77].
The brain vascular defects observed in Itgb8 null mutants are also shared by Tgfb1 and Tgfb3 
loss of function mutants. In addition, mutating the integrin-binding RGD binding site in 
Tgfb1 leads to early embryonic lethality [78]. Similarly, mice lacking both β6 and β8 integrins 
showed similar phenotypes as null mutants for Tgfb1 and Tgfb3 [78].
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More recently, integrin β8 and Nrp1 have been shown to mediate neuroepithelial-endo-
thelial cell interactions. β8 integrin in the neuroepithelium activates TGF-β signaling in 
ECs, while Nrp1 suppresses canonical TGF-β signaling, thus controlling normal sprouting 
angiogenesis [79]. Disruption of TGF-β signaling by targeting β8 integrin or Nrp1 results 
in excessive vessels sprouting and branching and formation of dysplastic glomeruloid-like 
vessels that are hemorrhagic [80].
The ανβ8-TGF-β connection in developmental angiogenesis in the brain also regulated 
neovascularization in the developing retina, where β8 integrin is expressed in astrocytes 
and Muller glial cells, a neuroepithelial cell type specifically found in the retina [81]. β8−/− 
retinas display abnormalities in the formation of the secondary vascular plexus, including 
impaired sprouting and formation of blood vessels with glomeruloid-like tufts. In addition, 
intraretinal hemorrhage was detected [81]. Furthermore, ablation of αν or β8 integrins but 
not of Tgfbr2 in astrocytes resulted in defects in angiogenesis, and blocking TGF-β1 with 
neutralizing antibodies affected paracrine signaling to ECs [81]. This work was confirmed 
later in a study showing that Tgfbr2 deletion in ECs of neonatal mice caused bleeding in 
the brain and vascular abnormalities, hemorrhage and deficiency in the formation of the 
deeper vascular network in the retina [82, 83]. Similarly, reduced Smad2 phosphorylation 
was observed in ECs from retina of Tgfbr2 knockout mice [82].
6. TGF-β in pathological angiogenesis
Genetic mutations in TGF-β signaling components are associated with various human vascu-
lar pathologies. For example, mutations in the TβRIII/endoglin gene are linked to hereditary 
hemorrhagic telangiectasia (HHT) and Osler-Rendu-Weber syndrome. The disease is charac-
terized, among others, by arteriovenous malformations (AVM) in the liver, brain and lung, 
telangiectases in skin and mucous membranes and recurrent epistaxis [84]. In trying to under-
stand AVM, it was proposed that TGF-β paracrine signaling from ECs to vascular smooth 
muscle cells and/or pericytes was reduced. As a consequence, vascular smooth muscle cell 
differentiation was affected and this resulted in fragile, leaky blood vessels [85]. Alternatively, 
other suggested mechanisms underlying AVM endothelial cell apoptosis and depletion of 
smooth muscle cells [6]. In addition, it was discovered that brain AVM present decreased 
 levels of integrin β8 which correlates with decreased TGF-β activation and signaling in ECs 
[86]. Mutations in human ITGAV and ITGB8 genes also predispose some families to spontane-
ous brain hemorrhage [87].
In cancer, angiogenesis is not properly regulated as it occurs in developmental and 
 physiological settings. Hypoxic conditions and proangiogenic factors released by tumor 
cells promote robust new blood vessel formation. The intratumoral vasculature is often 
 disorganized and leaky with hypertension and acidosis. Similarly, tumor ECs display 
 aneuploidy as well as centrosome and chromosomal amplifications [88]. The TGF-β  pathway 
is affected by either mutations in the main signaling components, in particular SMADs, or 
by altered expression of repressive factors (e.g., FOXG1, PI3K-AKT and C-MYC) (Figure 1). 
Analysis of copy number alterations using data from The Center Genome Atlas (TCGA) and 
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analyzed by cBioportal show that Smad2, 3 and 4 are mutated, deleted or amplified in sev-
eral tumor types, but especially in pancreatic, colorectal and gastric cancers [89, 90].
During tumor growth and progression, TGF-β plays a dual role as both an angiogenic and 
angiostatic factor [6]. In early-stage tumors, higher TGF-β expression levels are correlative 
with a better prognosis. TGF-βs exert cell cycle arrest by downregulating c-Myc and Ids 
1–3 in late G1 phase and by promoting the expression of cyclin-dependent protein kinase 
inhibitors [25]. As a proangiogenic factor, TGF-β pathway collaborates with VEGF, PDGF 
and bFGF in autocrine/paracrine signaling. In highly vascularized tumors, such as GBM and 
hepatocellular carcinoma (HCC), TGF-β levels are upregulated. In HCC cells, TGF-β induces 
the secretion of VEGF-A. Accordingly, inhibition of TGF-β by the TβRI/II synthetic kinase 
inhibitor LY2109761 showed decreased tumor size, vessel density and VEGF expression. This 
inhibitor also affected paracrine signaling between tumor cells and ECs. These effects on 
VEGF-A were dependent on SMAD2/3 expression levels [91]. Likewise, TGF-β inhibition in 
other cancer types such as colorectal cancer and GBM has also led to reduce intratumoral 
vascularization [59, 92–94]. Of note, the increase in angiogenesis caused by TGF-β in GBM 
was decreased by inhibition of the JNK pathway [95]. TGF-β family members also promote 
the secretion of MCP1 and TGF-α [96, 97], which impact inflammatory cells in the tumor 
microenvironment.
6.1. VEGF regulation by TGF-β
TGF-β promotes the expression of a major regulator of vasculogenesis and angiogenesis, 
VEGF. The VEGF family is comprised of a large group of secreted glycoproteins that inter-
act with various cell surface receptors. VEGF-A is expressed as four different isoforms (121, 
165, 189, 206 a.a.). Isoform 121 has low binding for heparan sulfate and diffuses away from 
its secreted location creating a chemogradient. Isoform 165 has higher affinity to heparan 
sulfate compared with 121, and it shows the highest mitogenic capacity among all isoforms. 
Finally, isoforms 189 and 206 have shown the highest binding capacity to bind heparan sul-
fates and are known to interact with other components of the ECM [33]. These ligands bind 
mainly three tyrosine kinase receptors (VEGFR) 1–3. VEGF-A has been a major therapeutic 
target in cancer due to its upregulation in many cancer types. Unfortunately, anti-angiogenic 
therapies that target VEGF-A, such as the neutralizing antibody Bevacizumab, have been 
unsuccessful in clinical studies where patients have shown resistance to anti-VEGF therapy. 
Similarly, in vitro studies performed in GBM cell lines indicated that irradiation enhances 
VEGF secretion [98–101].
FGF-2 induces VEGF expression in ECs via paracrine and autocrine signaling mechanisms 
[71]. TGF-β balances FGF-2 by suppressing the induction of plasminogen activator, a serine 
protease involved in the migration of cells, which is required in the formation of capillar-
ies during angiogenesis [102]. In contrast, TGF-β induces ECs apoptosis as part of capillary 
remodeling and at the same time promotes ECs expression of VEGF [103]. VEGF-A is an ECs 
survival factor and protects ECs from apoptosis [104]. More recent work has shown that VEGF 
targets p38MAPK resulting in ECs survival. In contrast, in the presence of TGF-β, FGF-2 is 
activated, promoting VEGF upregulation, p38MAPK activation and apoptosis [71].
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6.2. Upregulation of TGF-β in GBM
In GBM, an “angiogenic switch” marks the transition from low to more malignant tumors 
where ECs proliferate, resulting in a major increase in blood vessels. This excessive growth in 
vasculature was initially thought to be required for maintaining the aggressive growth rate of 
GBM. However, recent work suggests that these aberrant blood vessels are also required to 
maintain glioma stem cells (GSC), which are known to localize in close proximity to ECs in a 
perivascular niche. These cells secrete VEGF and express VEGFR2, and this complex is stabi-
lized by NRP1. This axis is involved in the self-renewal, survival and tumorigenic capacity of 
GSCs [105]. Recent work has shown that TGF-β induces differentiation of GSCs into pericytes 
to support vessel formation and tumor growth [106].
TGF-β cooperates in glioma angiogenesis by enhancing the expression of FGF, VEGF, 
PDGF-β, and CD44. Increased expression of FGF promotes VEGF expression. High levels 
of TGF-β in gliomas correlate with poor prognosis, and it is known to work in conjunction 
with the PDGF-β to increase GSCs proliferation [107]. In vSMC, TGF-β expression increases 
the levels of PDGF-β, its receptor (βPDGFR) and of EGF receptor (EGFR). βPDGFR promotes 
VEGF expression and secretion in ECs and signals through PI3K [108].
Angiogenesis in GBM develops by two mechanisms: microvascular cell proliferation and 
sprouting. The origin of microvascular proliferation seems to arise from hypoxia, where cells 
migrate away from the hypoxic center as a result of an increase in the levels of migration-
related genes. As a consequence, the center becomes necrotic and the cells surrounding it form 
a palisade, which secretes angiogenic factors such as VEGF. This promotes neighboring angio-
genesis, known as glomeruloid-like microvascular proliferation, composed of both endothe-
lial and smooth muscle cells. In contrast, the increase in angiogenic capillaries can be observed 
by staining with markers such as CD31 and Factor VIII-related antigen (Figure 4) [109].
TGF-β1-3 levels and endoglin-ALK1 signaling are elevated under hypoxic conditions. In addi-
tion, under hypoxia, Snail and Slug expression levels are increased. These genes are known to 
be involved in endothelial to mesenchymal transition and in sprouting angiogenesis and are 
regulated by TGF-β in ECs [110].
Integrins are important activators of the TGF-β pathway. They are important in regulating 
tumor angiogenesis by serving as receptors for ECM components, such as laminin, tenascin, 
fibronectin and collagens [111]. ανβ3 is a receptor for various secreted ECM proteins, such as 
von Willebrand factor, TSP-1, fibrinogen, proteolyzed collagen, fibronectin and vitronectin, 
and it is involved in angiogenesis and vascular remodeling. For instance, ανβ3 integrin asso-
ciates with MMP-2 in blood vessels of melanoma tumors, and this binding facilitates collagen 
degradation in vitro [112]. In GBM, TGF-β enhances ανβ3 integrin adhesion and expression 
and promotes integrin-mediated motility [111].
ανβ8 is expressed in GBM cell lines and primary tumors samples. GBM cell lines overexpress-
ing ανβ8 show an increase in proliferation but when injected into the brain generate tumors 
with a decrease in vascularity. Silencing αν or β8 integrin in transformed astrocytes or in 
human GBM cell lines leads to decreased in TGF-β signaling, resulting in increased tumor 
size, intratumoral hemorrhage and decreased tumor cell invasiveness [113, 114].
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In summary, TGF-β signaling is a crucial pathway in the angiogenesis of normal and tumor 
cells facilitating interactions between endothelial and epithelial cells. The vast majority of 
research has been focused on the activation of TGF-β, but more work is necessary to under-
stand how the pathway is repressed. This could help to move forward current therapeutic 
attempts to target components of the TGF-β signaling pathway.
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